Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

J & J Reaches Tentative Deal over Risperdal Marketing

By Pharmaceutical Processing | August 3, 2012

Johnson & Johnson revealed in a regulatory filing that it reached an “agreement in principle” with the U.S. Department of Justice and some states to settle investigations into marketing practices for Risperdal (risperidone) and two other products. “We won’t speculate on when a settlement will be finalized,” said Johnson & Johnson spokesman Al Wasilewski.

Specifically, the drugmaker indicated that it has reached a deal to settle three pending civil False Claims Act matters that are pending with authorities in Pennsylvania, California and Massachusetts related to the sales and marketing of Risperdal, Invega (paliperidone) and Natrecor (nesiritide). The settlement would also cover allegations that Johnson & Johnson provided pharmacy operator Omnicare with rebates and other payments linked to Risperdal.

The company added that it has also reached a tentative deal with representatives of a group of 38 states and the District of Columbia to settle non-Medicaid actions in connection with the sales and marketing of Risperdal and Invega. Johnson & Johnson said that for all of the preliminary agreements, “issues remain open that must be resolved before the settlements can be finalized.”

Johnson & Johnson noted that the settlements will not resolve all pending state litigation matters regarding Risperdal, adding that “some states may elect to opt out.” According to the drugmaker, among other states, Arkansas, Louisiana and South Carolina are not expected to participate in the settlements.

Recent reports suggested that Johnson & Johnson and the Department of Justice concluded an agreement for up to $2.2 billion, resolving probes into the company’s drug marketing practices. However, the final amount, which reportedly includes a criminal fine of about $400 million for the illegal promotion of Risperdal, is expected to be dependent on which states suing the drugmaker agree to the deal.

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards